FDA Approves Eighth Biosimilar Referencing AbbVie’s Humira

The FDA has approved Fresenius Kabi’s Idacio (adalimumab-aacf) as the eighth biosimilar to AbbVie’s blockbuster immunosuppressive drug Humira.

The indications for Idacio include rheumatoid arthritis, Crohn’s disease and plaque psoriasis.

The company plans to market the drug in July 2023 as a citrate-free, low-concentration formulation in a prefilled syringe or prefilled autoinjector pen.